- Home
- TECH vs VRNA Comparison
TECH vs VRNA Comparison
Compare TECH & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECH
- VRNA
- Stock Information
- Founded
- TECH 1976
- VRNA 2005
- Country
- TECH United States
- VRNA United Kingdom
- Employees
- TECH N/A
- VRNA N/A
- Industry
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- TECH Health Care
- VRNA Health Care
- Exchange
- TECH Nasdaq
- VRNA Nasdaq
- Market Cap
- TECH 7.8B
- VRNA 7.8B
- IPO Year
- TECH 1989
- VRNA 2017
- Fundamental
- Price
- TECH $49.89
- VRNA $92.20
- Analyst Decision
- TECH Buy
- VRNA Strong Buy
- Analyst Count
- TECH 11
- VRNA 7
- Target Price
- TECH $72.00
- VRNA $97.57
- AVG Volume (30 Days)
- TECH 2.5M
- VRNA 1.4M
- Earning Date
- TECH 08-06-2025
- VRNA 08-07-2025
- Dividend Yield
- TECH 0.64%
- VRNA N/A
- EPS Growth
- TECH N/A
- VRNA N/A
- EPS
- TECH 0.83
- VRNA N/A
- Revenue
- TECH $1,208,770,000.00
- VRNA $118,535,000.00
- Revenue This Year
- TECH $7.07
- VRNA $891.79
- Revenue Next Year
- TECH $5.88
- VRNA $78.94
- P/E Ratio
- TECH $60.23
- VRNA N/A
- Revenue Growth
- TECH 4.72
- VRNA N/A
- 52 Week Low
- TECH $46.01
- VRNA $14.14
- 52 Week High
- TECH $83.62
- VRNA $94.45
- Technical
- Relative Strength Index (RSI)
- TECH 49.63
- VRNA 78.05
- Support Level
- TECH $49.05
- VRNA $82.18
- Resistance Level
- TECH $51.66
- VRNA $93.74
- Average True Range (ATR)
- TECH 1.59
- VRNA 3.21
- MACD
- TECH 0.17
- VRNA 0.89
- Stochastic Oscillator
- TECH 47.40
- VRNA 92.52
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.